Left Ventricular Assist Device Driveline Infections

Cardiology Clinics

Volumn 29, Issue 4, 2011, Pages 515-527

  Pereda, Daniel ^a   Conte, John V ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Heart failure; Infection; Left ventricular assist device

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; FLUCONAZOLE; VANCOMYCIN;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; BACTERIUM ADHERENCE; BLOODSTREAM INFECTION; CELLULAR IMMUNITY; COMPUTER ASSISTED TOMOGRAPHY; COST; DEBRIDEMENT; DEVICE INFECTION; DISEASE CLASSIFICATION; DRIVELINE INFECTION; ERYTHEMA; FEVER; HEART TRANSPLANTATION; HOSPITAL COST; HOSPITAL READMISSION; HOST SUSCEPTIBILITY; HUMAN; HUMORAL IMMUNITY; IMPLANTATION; IMPLANTATION COST; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; LEFT VENTRICULAR ASSIST DEVICE; LEUKOCYTOSIS; MATERIAL COATING; MORTALITY; PATHOGENESIS; PHYSICAL ACTIVITY; PREVALENCE; PRIORITY JOURNAL; PUMP; PUMP POCKET INFECTION; REVIEW; RISK FACTOR; SURGICAL INFECTION; SURGICAL WOUND; SURVIVAL RATE; TREATMENT DURATION; VACUUM ASSISTED CLOSURE; WOUND CLOSURE; WOUND DRESSING;

ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; EQUIPMENT CONTAMINATION; HEART FAILURE; HEART-ASSIST DEVICES; HUMANS; NEGATIVE-PRESSURE WOUND THERAPY; POSTOPERATIVE CARE; PROSTHESIS IMPLANTATION; PROSTHESIS-RELATED INFECTIONS; RISK FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 80655144951     PISSN: 07338651     EISSN: 15582264     Source Type: Journal    
DOI: 10.1016/j.ccl.2011.08.004     Document Type: Review

References (66)

1. Rose E.A., Gelijns A.C., Moskowitz A.J., et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 2001, 345(20):1435-1443.
2. DeRose J.J., Argenziano M., Sun B.C., et al. Implantable left ventricular assist devices: an evolving long-term cardiac replacement therapy. Ann Surg 1997, 226(4):461-468. [discussion: 468-70].
3. Zierer A., Melby S.J., Voeller R.K., et al. Late-onset driveline infections: the Achilles' heel of prolonged left ventricular assist device support. Ann Thorac Surg 2007, 84(2):515-520.
4. Gordon S.M., Schmitt S.K., Jacobs M., et al. Nosocomial bloodstream infections in patients with implantable left ventricular assist devices. Ann Thorac Surg 2001, 72(3):725-730.
5. Oz M.C., Gelijns A.C., Miller L., et al. Left ventricular assist devices as permanent heart failure therapy: the price of progress. Ann Surg 2003, 238(4):577-583. [discussion: 583-5].
6. Elek S.D., Conen P.E. The virulence of Staphylococcus pyogenes for man; a study of the problems of wound infection. Br J Exp Pathol 1957, 38(6):573-586.
7. Didisheim P. Current concepts of thrombosis and infection in artificial organs. ASAIO J 1994, 40(2):230-237.
8. Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS). Manual of operations version 2.3. Appendix A: Adverse event definitions. Available at: 5. Accessed August 1, 2011. http://www.intermacs.org/2008.
9. John R., Pagani F.D., Naka Y., et al. Post-cardiac transplant survival after support with a continuous-flow left ventricular assist device: impact of duration of left ventricular assist device support and other variables. J Thorac Cardiovasc Surg 2010, 140(1):174-181.
10. McCarthy P.M., Schmitt S.K., Vargo R.L., et al. Implantable LVAD infections: implications for permanent use of the device. Ann Thorac Surg 1996, 61(1):359-365. [discussion: 372-3].
11. Griffith B.P., Kormos R.L., Nastala C.J., et al. Results of extended bridge to transplantation: window into the future of permanent ventricular assist devices. Ann Thorac Surg 1996, 61(1):396-398. [discussion: 407].
12. Oaks T.E., Pae W.E., Miller C.A., et al. Combined registry for the clinical use of mechanical ventricular assist pumps and the total artificial heart in conjunction with heart transplantation: fifth official report-1990. J Heart Lung Transplant 1991, 10(5 Pt 1):621-625.
13. Argenziano M., Catanese K.A., Moazami N., et al. The influence of infection on survival and successful transplantation in patients with left ventricular assist devices. J Heart Lung Transplant 1997, 16(8):822-831.
14. Prendergast T.W., Todd B.A., Beyer A.J., et al. Management of left ventricular assist device infection with heart transplantation. Ann Thorac Surg 1997, 64(1):142-147.
15. Chinn R., Dembitsky W., Eaton L., et al. Multicenter experience: prevention and management of left ventricular assist device infections. ASAIO J 2005, 51(4):461-470.
16. Holman W.L., Park S.J., Long J.W., et al. Infection in permanent circulatory support: experience from the REMATCH trial. J Heart Lung Transplant 2004, 23(12):1359-1365.
17. Miller L.W., Pagani F.D., Russell S.D., et al. Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med 2007, 357(9):885-896.
18. Raymond A.L., Kfoury A.G., Bishop C.J., et al. Obesity and left ventricular assist device driveline exit site infection. ASAIO J 2010, 56(1):57-60.
19. Gordon R.J., Quagliarello B., Lowy F.D. Ventricular assist device-related infections. Lancet Infect Dis 2006, 6(7):426-437.
20. Simon D., Fischer S., Grossman A., et al. Left ventricular assist device-related infection: treatment and outcome. Clin Infect Dis 2005, 40(8):1108-1115.
21. Jarvik R., Westaby S., Katsumata T., et al. LVAD power delivery: a percutaneous approach to avoid infection. Ann Thorac Surg 1998, 65(2):470-473.
22. Gristina A.G., Giridhar G., Gabriel B.L., et al. Cell biology and molecular mechanisms in artificial device infections. Int J Artif Organs 1993, 16(11):755-763.
23. Choi L., Choudhri A.F., Pillarisetty V.G., et al. Development of an infection-resistant LVAD driveline: a novel approach to the prevention of device-related infections. J Heart Lung Transplant 1999, 18(11):1103-1110.
24. Garatti A., Giuseppe B., Russo C.F., et al. Drive-line exit-site infection in a patient with axial-flow pump support: successful management using vacuum-assisted therapy. J Heart Lung Transplant 2007, 26(9):956-959.
25. Sun B.C., Catanese K.A., Spanier T.B., et al. 100 long-term implantable left ventricular assist devices: the Columbia Presbyterian interim experience. Ann Thorac Surg 1999, 68(2):688-694.
26. Hetzer R., Weng Y., Potapov E.V., et al. First experiences with a novel magnetically suspended axial flow left ventricular assist device. Eur J Cardiothorac Surg 2004, 25(6):964-970.
27. Siegenthaler M.P., Martin J., Pernice K., et al. The Jarvik 2000 is associated with less infections than the HeartMate left ventricular assist device. Eur J Cardiothorac Surg 2003, 23(5):748-754. [discussion: 754-5].
28. Vitali E., Lanfranconi M., Ribera E., et al. Successful experience in bridging patients to heart transplantation with the MicroMed DeBakey ventricular assist device. Ann Thorac Surg 2003, 75(4):1200-1204.
29. Maki D.G., Stolz S.M., Wheeler S., et al. Prevention of central venous catheter-related bloodstream infection by use of an antiseptic-impregnated catheter. A randomized, controlled trial. Ann Intern Med 1997, 127(4):257-266.
30. McKellar S.H., Allred B.D., Marks J.D., et al. Treatment of infected left ventricular assist device using antibiotic-impregnated beads. Ann Thorac Surg 1999, 67(2):554-555.
31. Westaby S., Siegenthaler M., Beyersdorf F., et al. Destination therapy with a rotary blood pump and novel power delivery. Eur J Cardiothorac Surg 2010, 37(2):350-356.
32. Gesler W., Smith R., DeDecker P.G., et al. Updated feasibility trial experience with the Viaderm percutaneous access device. ASAIO J 2004, 50(4):349-353.
33. Okamoto E., Yamamoto Y., Akasaka Y., et al. A new transcutaneous energy transmission system with hybrid energy coils for driving an implantable biventricular assist device. Artif Organs 2009, 33(8):622-626.
34. Rintoul T.C., Dolgin A. Thoratec transcutaneous energy transformer system: a review and update. ASAIO J 2004, 50(4):397-400.
35. Slaughter M.S., Myers T.J. Transcutaneous energy transmission for mechanical circulatory support systems: history, current status, and future prospects. J Card Surg 2010, 25(4):484-489.
36. Patti J.M., Allen B.L., McGavin M.J., et al. MSCRAMM-mediated adherence of microorganisms to host tissues. Annu Rev Microbiol 1994, 48:585-617.
37. Padera R.F. Infection in ventricular assist devices: the role of biofilm. Cardiovasc Pathol 2006, 15(5):264-270.
38. Arrecubieta C., Toba F.A., von Bayern M., et al. SdrF, a Staphylococcus epidermidis surface protein, contributes to the initiation of ventricular assist device driveline-related infections. PLoS Pathog 2009, 5(5):e1000411.
39. Shoham S., Miller L.W. Cardiac assist device infections. Curr Infect Dis Rep 2009, 11(4):268-273.
40. Costerton J.W., Lewandowski Z., Caldwell D.E., et al. Microbial biofilms. Annu Rev Microbiol 1995, 49:711-745.
41. Dasgupta M.K. Biofilms and infection in dialysis patients. Semin Dial 2002, 15(5):338-346.
42. Hall-Stoodley L., Costerton J.W., Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases. Nat Rev Microbiol 2004, 2(2):95-108.
43. Otto M. Staphylococcus epidermidis-the 'accidental' pathogen. Nat Rev Microbiol 2009, 7(8):555-567.
44. Toba F.A., Akashi H., Arrecubieta C., et al. Role of biofilm in Staphylococcus aureus and Staphylococcus epidermidis ventricular assist device driveline infections. J Thorac Cardiovasc Surg 2011, 141(5):1259-1264.
45. Dickinson G.M., Bisno A.L. Infections associated with prosthetic devices: clinical considerations. Int J Artif Organs 1993, 16(11):749-754.
46. Richards G.K., Gagnon R.F. An assay of Staphylococcus epidermidis biofilm responses to therapeutic agents. Int J Artif Organs 1993, 16(11):777-788.
47. Costerton J.W., Khoury A.E., Ward K.H., et al. Practical measures to control device-related bacterial infections. Int J Artif Organs 1993, 16(11):765-770.
48. Ankersmit H.J., Edwards N.M., Schuster M., et al. Quantitative changes in T-cell populations after left ventricular assist device implantation: relationship to T-cell apoptosis and soluble CD95. Circulation 1999, 100(19 Suppl):II211-II215.
49. Ankersmit H.J., Tugulea S., Spanier T., et al. Activation-induced T-cell death and immune dysfunction after implantation of left-ventricular assist device. Lancet 1999, 354(9178):550-555.
50. Kimball P.M., Flattery M., McDougan F., et al. Cellular immunity impaired among patients on left ventricular assist device for 6 months. Ann Thorac Surg 2008, 85(5):1656-1661.
51. Yamani M.H., Chuang H.H., Ozduran V., et al. The impact of hypogammaglobulinemia on infection outcome in patients undergoing ventricular assist device implantation. J Heart Lung Transplant 2006, 25(7):820-824.
52. Bratzler D.W., Houck P.M. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Clin Infect Dis 2004, 38(12):1706-1715.
53. Schaffer J.M., Allen J.G., Weiss E.S., et al. Infectious complications after pulsatile-flow and continuous-flow left ventricular assist device implantation. J Heart Lung Transplant 2011, 30(2):164-174.
54. Tjan T.D., Asfour B., Hammel D., et al. Wound complications after left ventricular assist device implantation. Ann Thorac Surg 2000, 70(2):538-541.
55. Pasque M.K., Hanselman T., Shelton K., et al. Surgical management of Novacor drive-line exit site infections. Ann Thorac Surg 2002, 74(4):1267-1268.
56. Baradarian S., Stahovich M., Krause S., et al. Case series: clinical management of persistent mechanical assist device driveline drainage using vacuum-assisted closure therapy. ASAIO J 2006, 52(3):354-356.
57. Yuh D.D., Albaugh M., Ullrich S., et al. Treatment of ventricular assist device driveline infection with vacuum-assisted closure system. Ann Thorac Surg 2005, 80(4):1493-1495.
58. Argenta L.C., Morykwas M.J. Vacuum-assisted closure: a new method for wound control and treatment: clinical experience. Ann Plast Surg 1997, 38(6):563-576. [discussion: 577].
59. Martin S.I., Wellington L., Stevenson K.B., et al. Effect of body mass index and device type on infection in left ventricular assist device support beyond 30 days. Interact Cardiovasc Thorac Surg 2010, 11(1):20-23.
60. Holman W.L., Kirklin J.K., Naftel D.C., et al. Infection after implantation of pulsatile mechanical circulatory support devices. J Thorac Cardiovasc Surg 2010, 139(6):1632-1636.e2.
61. Aslam S., Hernandez M., Thornby J., et al. Risk factors and outcomes of fungal ventricular-assist device infections. Clin Infect Dis 2010, 50(5):664-671.
62. Saito S., Matsumiya G., Sakaguchi T., et al. Risk factor analysis of long-term support with left ventricular assist system. Circ J 2010, 74(4):715-722.
63. Pagani F.D., Miller L.W., Russell S.D., et al. Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. J Am Coll Cardiol 2009, 54(4):312-321.
64. Morshuis M., El-Banayosy A., Arusoglu L., et al. European experience of DuraHeart magnetically levitated centrifugal left ventricular assist system. Eur J Cardiothorac Surg 2009, 35(6):1020-1027. [discussion: 1027-8].
65. Pae W.E., Connell J.M., Adelowo A., et al. Does total implantability reduce infection with the use of a left ventricular assist device? The LionHeart experience in Europe. J Heart Lung Transplant 2007, 26(3):219-229.
66. Monkowski D.H., Axelrod P., Fekete T., et al. Infections associated with ventricular assist devices: epidemiology and effect on prognosis after transplantation. Transpl Infect Dis 2007, 9(2):114-120.